Revenue Breakdown
Composition ()
No data
Revenue Streams
AbbVie Inc (ABBV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Immunology-SKYRIZI, accounting for 28.2% of total sales, equivalent to $4.42B. Other significant revenue streams include Immunology-RINVOQ and Immunology-HUMIRA. Understanding this composition is critical for investors evaluating how ABBV navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, AbbVie Inc maintains a gross margin of 72.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 34.97%, while the net margin is 25.47%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ABBV converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ABBV competes directly with industry leaders such as ONC and MRK. With a market capitalization of $394.89B, it holds a leading position in the sector. When comparing efficiency, ABBV's gross margin of 72.64% stands against ONC's 86.09% and MRK's 79.73%. Such benchmarking helps identify whether AbbVie Inc is trading at a premium or discount relative to its financial performance.
